Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

Dr Ciara Murphy

Dr Ciara Murphy, BSc, PhD
StAR Lecturer

Tel +353 1 402 5053

Dr Ciara Murphy began her career with a first class Honours degree (BSc) in Biological Sciences from the National University of Ireland, Maynooth. From there she went on to the Royal College of Surgeons in Ireland (RCSI) where she completed her PhD in Bone Tissue Engineering in 2010, studying the effect of collagen-based scaffold architecture on cell behaviour; specifically cell migration and differentiation.

As a post-doctoral fellow, Ciara was recruited to Prof. David Little's orthopaedic research group in the Children's Hospital at Westmead, Sydney, Australia. It was during this time that her research focus moved towards orthopaedic medicine, whereby she applied her experience in tissue engineering with Prof. Little's expertise in orthopaedic drug therapies to develop novel therapeutic approaches to augment bone healing in challenging orthopaedic defects. This led to a successful project which applied Teriparatide (PTH(1-34)) treatment as a mechanism for ameliorating bisphosphonate burden within bisphosphonate loaded fractures, for which Ciara was awarded the prestigious New Investigator Recognition Award at the 2014 International Orthopaedic Research Society (ORS).

In 2015 Ciara returned to Ireland, taking up a position as Assistant Professor in the School of Medicine in University College Dublin (UCD). Upon her return she was awarded a prestigious Marie Curie Individual Fellowship to begin her independent research career in the development of injectable biomaterials as therapeutic platforms for atypical femoral fractures.

Ciara joined the Tissue Engineering Research Group (TERG) and RCSI as a StAR Research Lecturer in 2017. Her research interest is in developing advanced biomaterials as innovative platforms for disease model systems and targeted therapeutic delivery systems for tissue repair. The main focus of her research is the study of cell-matrix interactions in metabolic bone disease, such as osteoporosis, to design minimally invasive targeted therapies and technologies to treat metabolically impaired bone defects.

PI Profile